AVM Biotechnology was founded in 2008 by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 35 patents, Dr. Deisher leads a team of scientists in researching game-changing stem cell technologies. Our lead molecule, AVM0703, received FDA approval in April 2020 to proceed with Phase I/II clinical trials for the treatment of lymphoid malignancies. AVM Biotechnology’s research shows that AVM0703 may also be an effective therapeutic treatment against viruses, including COVID-19. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has filed with the FDA for the approval to proceed with clinical trials against this deadly virus.
We at AVM Biotechnology seek to improve the availability and level of care for patients around the world. Our mission is to deliver drugs that work fast and are safe, effective, affordable, and available. At AVM, we strive to develop products that improve outcomes without additional suffering because we believe that side effects from the treatments of cancers or infections should never be worse than the diseases themselves.
